Pharmacologic interception in T-cell leukemia 1A associated pathways as a treatment rationale for chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1375-1378

  Popal, Wagma ^a   Boucas, Jorge ^a   Peer Zada, Abdul Ali ^a   Herling, Marco ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

AKT; CLL; mTOR; phosphodiesterase inhibitor; TCL1

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; FLUDARABINE; HERMES ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; PROTEIN KINASE ZAP 70; R 406; RITUXIMAB; ROLIPRAM; T CELL LEUKEMIA 1A; UNCLASSIFIED DRUG; VASCULOTROPIN;

B LYMPHOCYTE; CANCER MODEL; CANCER RESISTANCE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; COMPLEX FORMATION; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; HUMAN; MICROENVIRONMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, T-CELL; MICE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 77955452651     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.505064     Document Type: Short Survey

References (16)

1. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002;99:6955-6960.
2. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16- 1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010;17: 28-40.
3. Herling M, Patel KA, Weit N, et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009;114: 4675-4686.
4. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia 2006;20:280-285.
5. Hoyer KK, Herling M, Bagrintseva K, et al. T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation. J Immunol 2005;175:864-873.
6. Herling M, Patel KA, Hsi ED, et al. TCL1 in B-cell tumors retains its normal B-cell pattern of regulation and is a marker of differentiation stage. Am J Surg Pathol 2007;31: 1123-1129.
7. Laine J, Kunstle G, Obata T, Sha M, Noguchi M. The protooncogene TCL1 is an Akt kinase coactivator. Mol Cell 2000;6:395-407.
8. Kunstle G, Laine J, Pierron G, et al. Identification of Akt association and oligomerization domains of the Akt kinase coactivator TCL1. Mol Cell Biol 2002;22:1513-1525.
9. Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008;111:328-337.
10. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-644.
11. Quiroga MP, Balakrishnan K, Kurtova AV, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009;114:1029-1037.
12. Lerner A, Kim DH, Lee R. The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. Leuk Lymphoma 2000;37:39-51.
13. Kuraishy AI, French SW, Sherman M, et al. TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. Proc Natl Acad Sci USA 2007;104:10175-10180.
14. Misra UK, Kaczowka SJ, Pizzo SV. Interaction between TCL1 and Epac1 in the activation of Akt kinases in plasma membranes and nuclei of 8-CPT-2-O-Me-cAMP-stimulated macrophages. Cell Signal 2008;20:130-138.
15. Pekarsky Y, Palamarchuk A, Maximov V, et al. TCL1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL. Proc Natl Acad Sci USA 2008;105:19643-19648.
16. Ropars V, Despouy G, Stern MH, Benichou S, Roumestand C, Arold ST. The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB. PLoS One 2009;4: e6567.